leadf
logo-loader
viewCelavie Biosciences

Celavie Biosciences advancing its five year exploratory study in Parkinson's Disease

Celavie Biosciences CEO Sandy Solomon sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York. The California-based company is developing regenerative stem cell therapies to treat Parkinson’s disease and other central nervous system disorders.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

CO2 GRO sees 20% higher pepper yields though 10 weeks of Hidroexpo Feasibility

CO2 GRO (CVE: GROW- OTCQB: BLONF) Vice President of Sales and Strategic Alliances Aaron Archibald joined Steve Darling from Proactive to bring details the company has seen very good results from their CO2 Delivery Solution commercial feasibility on greenhouse-grown peppers with Hidroexpo in...

1 day, 1 hour ago

2 min read